Skip to main content

Table 4 Baseline clinical data of patients enrolled in the REAL study

From: The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil

Clinical Data Absolute value or % n
Disease duration, years, median (range) 12.7 (0.7–56.9) 1114
Time from symptoms to diagnosis, months, median (range) 12 (1–457) 1078
Time from symptoms to 1st DMARD, months, median (range) 12 (1–624) 994
Patients with ≥1 extra-articular manifestation, % 23.3 1115
Positive rheumatoid factor, % 78.2 1105
Positive anti-citrullinated peptide antibody, % 77.2 477
Erosive disease, % 54.9 1095
Patients fulfilling classification criteria, %:
 ARA 1987 90.0 1115
 ACR/EULAR 2010 90.9 1115
 Both 80.8 1115
Drugs in use, %:
 Glucocorticoids 47.4 1115
 Nonsteroidal anti-inflammatory drugs 9.1 1115
 Synthetic DMARD 90.9 1115
 Methotrexate 66.5 1115
 Biologic DMARD 35.7 1115
 Biologic DMARD in monotherapy 5,6 1115
ESR, median (range) 21 (1–140) 923
CRP median (range) 0.7 (0–76.1) 944
Pain (VAS 0–100), median (range) 40 (0–100) 1115
Fatigue (VAS 0–100), median (range) 40 (0–100) 1115
Global health assessment (VAS 0–100), median (range) 38 (0–100) 1115
DAS28-ESR, median (range) 3.5 (0.3–8.2) 923
 Remission 26.2  
 Low disease activity 15.1  
 Moderate disease activity 41.8  
 High disease activity 16.9  
CDAI, median (range) 9 (0–70) 1113
 Remission 20.1  
 Low disease activity 33.2  
 Moderate disease activity 27.5  
 High disease activity 19.2  
HAQ-DI, median (range) 0.875 (0–3) 1111
SF-12 physical, median (range) 36.1 (17.5–55.9) 1079
SF-12 mental, median (range) 47.1 (14.3–72.0) 1079
  1. ARA American Rheumatism Association, ACR American College of Rheumatology, EULAR European League Against Rheumatism, DMARD disease-modifying antirheumatic drug, VAS visual analogue scale, ESR erythrocyte sedimentation rate (mm/first hour), CRP C-reactive protein (mg/dL), DAS28 Disease Activity Score 28-joint count, CDAI: Clinical Disease Activity Index, HAQ Health Assessment Questionnaire-Disability Index, SF-12 12-Item Short-Form Health Survey